Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK-Reference-Cited by-同舟云学术

Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK

Published:2020-10-27 Issue:12 Volume:23 Page:1640-1652
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Narayan Omendra¹²,Bentley Anthony³,Mowbray Katie⁴,Hermansson Monika⁴,Pivonka Dominic⁴,Kemadjou Eric Ngonga⁵,Belsey Jonathan⁵

Affiliation:

1. Royal Manchester Children’s Hospital, Manchester, UK

2. Paediatric Respiratory Medicine, University of Manchester, Manchester, UK

3. Mtech Access Limited, Bicester, UK

4. AbbVie Limited, Maidenhead, UK

5. JB Medical Limited, Sudbury, UK

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1836923

Reference55 articles.

1. Respiratory-Syncytial-Virus Infections, Reinfections and Immunity

2. Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation Statement on immunisation for Respiratory Syncytial Virus.

3. Public Health England. Immunisation against infectious disease (Green Book). Chapter 27a Respiratory syncytial virus. 2015.

4. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England

5. Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes;Infectious Diseases and Therapy;2024-09-05

2. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia;BMC Infectious Diseases;2024-04-19

3. Prevalence, Prevention and Management of Bronchopulmonary Dysplasia;Research and Reports in Neonatology;2024-01

4. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States;Pediatrics & Neonatology;2023-09

5. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age;PLOS ONE;2023-08-10